Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF

This study has been terminated.
(Sponsor closed study)
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01367275
First received: June 3, 2011
Last updated: January 7, 2015
Last verified: January 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: November 2013
  Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)